- TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
- TriSalus Reports Q1 2024 Financial Results and Business Update
- TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
- TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
- TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
- TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
- TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
- TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
- TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
- TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
More ▼
Key statistics
On Friday, TriSalus Life Sciences Inc (TLSI:NMQ) closed at 7.16, 115.66% above the 52 week low of 3.32 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.62 |
---|---|
High | 7.62 |
Low | 7.10 |
Bid | 7.20 |
Offer | 11.00 |
Previous close | 7.44 |
Average volume | 62.18k |
---|---|
Shares outstanding | 27.16m |
Free float | 12.60m |
P/E (TTM) | -- |
Market cap | 194.46m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼